PMID- 36275666
OWN - NLM
STAT- MEDLINE
DCOM- 20221025
LR  - 20230721
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Strategies to overcome DC dysregulation in the tumor microenvironment.
PG  - 980709
LID - 10.3389/fimmu.2022.980709 [doi]
LID - 980709
AB  - Dendritic cells (DCs) play a key role to modulate anti-cancer immunity in the 
      tumor microenvironment (TME). They link innate to adaptive immunity by processing 
      and presenting tumor antigens to T cells thereby initiating an anti-tumor 
      response. However, subsets of DCs also induce immune-tolerance, leading to tumor 
      immune escape. In this regard, the TME plays a major role in adversely affecting 
      DC function. Better understanding of DC impairment mechanisms in the TME will 
      lead to more efficient DC-targeting immunotherapy. Here, we review the different 
      subtypes and functions of DCs in the TME, including conventional DCs, 
      plasmacytoid DC and the newly proposed subset, mregDC. We further focus on how 
      cancer cells modulate DCs to escape from the host's immune-surveillance. Immune 
      checkpoint expression, small molecule mediators, metabolites, deprivation of 
      pro-immunogenic and release of pro-tumorigenic cytokine secretion by tumors and 
      tumor-attracted immuno-suppressive cells inhibit DC differentiation and function. 
      Finally, we discuss the impact of established therapies on DCs, such as immune 
      checkpoint blockade. Creative DC-targeted therapeutic strategies will be 
      highlighted, including cancer vaccines and cell-based therapies.
CI  - Copyright (c) 2022 Mestrallet, Sone and Bhardwaj.
FAU - Mestrallet, Guillaume
AU  - Mestrallet G
AD  - Division of Hematology and Oncology, Hess Center for Science & Medicine, Tisch 
      Cancer Institute, Precision Immunology Institute, Icahn School of Medicine at 
      Mount Sinai, New York, NY, United States.
FAU - Sone, Kazuki
AU  - Sone K
AD  - Division of Hematology and Oncology, Hess Center for Science & Medicine, Tisch 
      Cancer Institute, Precision Immunology Institute, Icahn School of Medicine at 
      Mount Sinai, New York, NY, United States.
FAU - Bhardwaj, Nina
AU  - Bhardwaj N
AD  - Division of Hematology and Oncology, Hess Center for Science & Medicine, Tisch 
      Cancer Institute, Precision Immunology Institute, Icahn School of Medicine at 
      Mount Sinai, New York, NY, United States.
AD  - Extramural Member, Parker Institute for Cancer Immunotherapy, San Francisco, CA, 
      United States.
LA  - eng
GR  - R01 AI081848/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20221006
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Cancer Vaccines)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cytokines)
SB  - IM
MH  - Humans
MH  - Tumor Microenvironment
MH  - *Cancer Vaccines
MH  - Immune Checkpoint Inhibitors
MH  - *Neoplasms/therapy
MH  - Antigens, Neoplasm
MH  - Cytokines
PMC - PMC9583271
OTO - NOTNLM
OT  - DC
OT  - Treg
OT  - cytokines
OT  - immune checkpoint inhibitors
OT  - mregDC
OT  - tumor microenvironment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/25 06:00
MHDA- 2022/10/26 06:00
PMCR- 2022/01/01
CRDT- 2022/10/24 04:02
PHST- 2022/06/28 00:00 [received]
PHST- 2022/09/16 00:00 [accepted]
PHST- 2022/10/24 04:02 [entrez]
PHST- 2022/10/25 06:00 [pubmed]
PHST- 2022/10/26 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.980709 [doi]
PST - epublish
SO  - Front Immunol. 2022 Oct 6;13:980709. doi: 10.3389/fimmu.2022.980709. eCollection 
      2022.